Canobbio L, Rubagotti A, Miglietta L, Cannata D, Curotto A, Amoroso D, Boccardo F
Department of Medical Oncology II, National Institute for Cancer Research, Genoa, Italy.
J Cancer Res Clin Oncol. 1995;121(12):753-6. doi: 10.1007/BF01213322.
A group of 73 patients with advanced renal cell carcinoma, treated in different phase II trials with interferon alpha and/or interleukin-2, have been evaluated to identify potential baseline prognostic factors predicting their survival. The eligibility criteria were very similar across studies and included ECOG performance status < or = 2, measurable or evaluable disease and no CNS metastases. The overall response rate was 8%. The overall survival was 33% at 2 years and 18% at 1 year. In the univariate analysis three prognostic factors were correlated with disease outcome: ECOG performance status (0 versus > or = 1), time from diagnosis to treatment (< or = 12 months versus > 12 months) and number of metastatic sites (1 versus > or = 2). Multivariate analysis identified ECOG performance status and number of metastatic sites as important prognostic factors for survival. The true impact on patient survival of the selection of patients rather than the treatment itself should be evaluated in controlled trials.
一组73例晚期肾细胞癌患者，在不同的II期试验中接受了α干扰素和/或白细胞介素-2治疗，已对其进行评估以确定预测其生存的潜在基线预后因素。各研究的纳入标准非常相似，包括东部肿瘤协作组（ECOG）体能状态≤2、疾病可测量或可评估且无中枢神经系统转移。总缓解率为8%。2年总生存率为33%，1年总生存率为18%。单因素分析中，三个预后因素与疾病转归相关：ECOG体能状态（0对比≥1）、从诊断到治疗的时间（≤12个月对比>12个月）以及转移部位数量（1对比≥2）。多因素分析确定ECOG体能状态和转移部位数量是生存的重要预后因素。应在对照试验中评估患者选择而非治疗本身对患者生存的真正影响。
